New drug cocktail aims to stop bladder cancer recurrence after surgery

NCT ID NCT06682728

Recruiting now Disease control Sponsor: University of California, Irvine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether combining two drugs—sacituzumab govitecan and nivolumab—after surgery can keep high-risk bladder cancer from coming back. About 23 adults who had their bladder or part of their urinary tract removed will receive the drugs intravenously. The main goal is to see how many patients remain cancer-free at 6 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sacituzumab govitecan and nivolumab
What this could lead to: If successful, this combination could reduce the chance of cancer returning after surgery for high-risk bladder cancer patients.
What could go wrong: This is a small, early-phase trial with only 23 participants, so results may not apply broadly. The drugs can cause side effects like fatigue, nausea, and immune-related reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MUSCLE-INVASIVE BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infiltrating bladder urothelial carcinoma transitional cell carcinoma urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MUSCLE-INVASIVE BLADDER CANCER UROTHELIAL CARCINOMA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Chao Family Comprehensive Cancer Center, University of California, Irvine
RECRUITING

Orange, California, 92868, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.